Skip to main content

Advertisement

SpringerLink
Log in

Detection and Clinical Management of Cervical Pathology in the Era of HPV

  • Management of HPV and Associated Cervical Lesions (C-H Lai, Section Editor)
  • Published:
Current Obstetrics and Gynecology Reports Aims and scope Submit manuscript

Abstract

While infection with high-risk (HR) human papillomavirus (HPV) is central to cervical carcinogenesis, natural history studies show that both low- and high-grade cervical intraepithelial neoplasia (CIN) lesions are very early manifestations of HR-HPV infection. Most high- and low-grade lesions are self limited, and only those HR-HPV infections capable of persisting for decades are at risk of progression. Our new understanding of the natural history of HPV associated lesions has dramatically changed cervical cancer screening, classification and management of cervical lesions. As an increasing proportion of women are vaccinated against those oncogenic-HPVs responsible for most cervical cancers, the positive predictive value of cytology and HPV testing for identification of women at risk for cancer will decrease. New biomarkers, capable of identifying those high-grade lesions which are truly at risk of progression and need treatment, will need to be developed to serve as adjuncts to morphology and patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174(4):679–89.

    Article  CAS  PubMed  Google Scholar 

  2. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis. 1993;20(5):286–9.

    Article  CAS  PubMed  Google Scholar 

  3. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004;189(1):46–50.

    Article  PubMed  Google Scholar 

  4. Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol. 1989;74(6):950–4.

    CAS  PubMed  Google Scholar 

  5. Ferenczy A, Bergeron C, Richart RM. Human papillomavirus DNA in CO2 laser-generated plume of smoke and its consequences to the surgeon. Obstet Gynecol. 1990;75(1):114–8.

    CAS  PubMed  Google Scholar 

  6. Medeiros LR, Ethur ABM, Hilgert JB, et al. Vertical transmission of the human papillomavirus: a systematic quantitative review. Cad Saude Publica. 2005;21(4):1006–15.

    Article  PubMed  Google Scholar 

  7. Tseng CJ, Liang CC, Soong YK, Pao CC. Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet Gynecol. 1998;91(1):92–6.

    Article  CAS  PubMed  Google Scholar 

  8. Stanley M. HPV – immune response to infection and vaccination. Infect Agent Cancer. 2010;5:19. Great review of the immune mechanisms in response to HPV infection and HPV vaccination.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A. 2012;109(26):10516–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24 Suppl 1:S4–15.

    Article  Google Scholar 

  11. Fisher M, Rosenfeld WD, Burk RD. Cervicovaginal human papillomavirus infection in suburban adolescents and young adults. J Pediatr. 1991;119(5):821–5.

    Article  CAS  PubMed  Google Scholar 

  12. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst. 1991;83(14):997–1003.

    Article  CAS  PubMed  Google Scholar 

  13. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53(6):919–23.

    Article  CAS  PubMed  Google Scholar 

  14. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1992;84(6):394–8.

    Article  CAS  PubMed  Google Scholar 

  15. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32:S16–24.

    Article  PubMed  Google Scholar 

  16. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121(12):4593–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288(14):1749–57.

    Article  PubMed  Google Scholar 

  18. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.

    Article  CAS  PubMed  Google Scholar 

  19. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12(6):485–90.

    PubMed  Google Scholar 

  20. Jaisamrarn U, Castellsague X, Garland SM, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomized PATRICIA study. PLoS One. 2013;8(11):e79260. Large prospective study with valuable data on HPV infection clearanc, persistence and risk of progression.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831–6.

    Article  CAS  PubMed  Google Scholar 

  22. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415–23.

    Article  CAS  PubMed  Google Scholar 

  23. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999;91(11):954–60.

    Article  CAS  PubMed  Google Scholar 

  24. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001;183(1):8–15.

    Article  CAS  PubMed  Google Scholar 

  25. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.

    Article  PubMed  Google Scholar 

  26. Slavinsky III J, Kissinger P, Burger L, Boley A, DiCarlo RP, Hagensee ME. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS. 2001;12(8):516–23.

    Article  PubMed  Google Scholar 

  27. Touze A, de Sanjose S, Coursaget P, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol. 2001;39(12):4344–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003;89(7):1248–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Winer RL, Koutsky LA. Chapter 28: genital human papillomavirus infection. In: Holmes KK, Sparling PF, Stamm WE, et al., editors. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill; 2008. p. 489–508.

    Google Scholar 

  30. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186(10):1396–402.

    Article  PubMed  Google Scholar 

  31. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174(5):927–36.

    Article  CAS  PubMed  Google Scholar 

  32. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev. 2004;13(1):110–6.

    Article  CAS  PubMed  Google Scholar 

  33. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911–9.

    Article  CAS  PubMed  Google Scholar 

  34. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol. 1999;80(Pt 2):399–408.

    PubMed  Google Scholar 

  35. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–65.

    Article  CAS  PubMed  Google Scholar 

  36. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24(27–28):5571–83.

    Article  CAS  PubMed  Google Scholar 

  37. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010;28(38):6247–55.

    Article  PubMed  Google Scholar 

  38. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009;27(41):5612–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 2007;107(2 Supp 1):S2–5.

    Article  CAS  PubMed  Google Scholar 

  40. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst. 2010;102(21):1653–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169(2):235–40.

    Article  CAS  PubMed  Google Scholar 

  43. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315–24.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Nobbenhuis MA, Walboomers JM, Helmerjorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prosepective study. Lancet. 1999;354(9172):20–5.

    Article  CAS  PubMed  Google Scholar 

  45. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478–88.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327(18):1272–8.

    Article  CAS  PubMed  Google Scholar 

  47. Trottier H, Mahnud SM, Lindsay L, et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev. 2009;18(3):854–62.

    Article  CAS  PubMed  Google Scholar 

  48. Ho GY, Burk RD, Klein S, et al. Persistent human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87(18):1365–71.

    Article  CAS  PubMed  Google Scholar 

  49. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor for cervical intraepithelial neoplasia. JAMA. 2001;286(24):3106–14.

    Article  CAS  PubMed  Google Scholar 

  50. Schiffman M, Herrero R, Desalle R. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76–84.

    Article  CAS  PubMed  Google Scholar 

  51. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218–26.

    Article  PubMed  Google Scholar 

  52. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107(1):18–27.

    Article  PubMed  Google Scholar 

  53. Woodman CB, Collins S. A critique of cohort studies examining the role of human papillomavirus infection in cervical neoplasia. BJOG. 2002;109(12):1311–8.

    Article  PubMed  Google Scholar 

  54. Kiviat NB, Critchlow CW, Kurman RJ. Reassessment of the morphological continuum of cervical intraepithelial lesions: does it reflect different stages in the progression to cervical carcinoma? IARC Sci Publ. 1992;119:59–66.

    PubMed  Google Scholar 

  55. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373–80. Prospective study investigating the natural history of CIN2 in adolescents and young women.

    Article  PubMed Central  PubMed  Google Scholar 

  56. McAllum B, Sykes PH, Sadler L, Macnab H, Simcock BJ, Mekhail AK. Is the treatment of CIN 2 always necessary in women under 25 years old? Am J Obstet Gynecol. 2011;205(5):478.e1–7.

    Google Scholar 

  57. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18–25.

    Article  PubMed Central  PubMed  Google Scholar 

  59. National Cancer Institute, Bethesda, MD. Surveillance, epidemiology, and end results program. At: seer.cancer.gov/statfacts/html/cervix.html. Accessed 20 Jan 2014.

  60. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141(7):680–9.

    CAS  PubMed  Google Scholar 

  61. Cuzick J, Szarewski A, Terry G, et al. Human papillomavirus testing in primary cervical screening. Lancet. 1995;345(8964):1533–6.

    Article  CAS  PubMed  Google Scholar 

  62. Sedlacek TV. Cost-effectiveness of methods to enhance sensitivity of Papanicolaou testing. Jama. 1999;282(15):1419–20.

    Article  CAS  PubMed  Google Scholar 

  63. Joste NE, Rushing L, Granados R, et al. Bethesda classification of cervicovaginal smears: reproducibility and viral correlates. Hum Pathol. 1996;27(6):581–5.

    Article  CAS  PubMed  Google Scholar 

  64. Ismail SM, Colclough AB, Dinnen JS, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989;298(6675):707–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Dalla Palma P, Giorgi Rossi P, Collina G, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol. 2009;132(1):125–32.

    Article  PubMed  Google Scholar 

  66. Miller AB. An epidemiological perspective on cancer screening. Clin Biochem. 1995;28(1):41–8.

    Article  CAS  PubMed  Google Scholar 

  67. NIH releases consensus statement on cervical cancer. Am Fam Physician. 1996;54(7):2310, 2315-6.

    Google Scholar 

  68. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42.

    Article  PubMed  Google Scholar 

  69. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46. Latest ASCCP Guidelines for the management of abnormal cervical cancer screening tests and precursor lesions.

    Article  PubMed  Google Scholar 

  70. Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst. 2006;98(2):92–100.

    Article  PubMed  Google Scholar 

  71. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24 Suppl 3:78–89.

    Article  Google Scholar 

  72. Carozzi F, Confortini M, Cecchini S, et al. Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer. 2005;105(1):2–7.

    PubMed  Google Scholar 

  73. Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev. 2013;3, CD008054.

    PubMed  Google Scholar 

  74. Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the Hybrid Capture II test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  75. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489–98.

    Article  CAS  PubMed  Google Scholar 

  76. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72.

    Article  CAS  PubMed  Google Scholar 

  77. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.

    Article  CAS  PubMed  Google Scholar 

  78. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589–97.

    Article  CAS  PubMed  Google Scholar 

  79. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492–501.

    Article  PubMed  Google Scholar 

  80. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7(7):547–55.

    Article  PubMed  Google Scholar 

  81. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104(1):232–46.

    Article  PubMed  Google Scholar 

  82. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 Suppl 10:29–41.

    Article  Google Scholar 

  83. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.

    Article  PubMed  Google Scholar 

  84. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol. 2009;46 Suppl 3:S1–4.

    Article  PubMed  Google Scholar 

  85. Ronco G, Dillner J, Elfstrom KM et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2013 Nov 1.

  86. Carozzi F, Visioli CB, Confortini M, et al. hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy. Br J Cancer. 2013;109(7):1766–74.

    Article  CAS  PubMed  Google Scholar 

  87. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.

    Article  PubMed Central  PubMed  Google Scholar 

  88. Lynge E, Rebolj M. Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol. 2009;6(12):699–706.

    Article  PubMed  Google Scholar 

  89. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005;93(8):862–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  90. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific performance of cervical cancer screening with primary HPV DNA test compared to conventional cytological screening in a randomised setting. J Natl Cancer Inst. 2009;101(23):1612–23.

    Article  CAS  PubMed  Google Scholar 

  91. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804.

    Article  PubMed Central  PubMed  Google Scholar 

  92. Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1968;5:748–84.

    Google Scholar 

  93. American Society for Colposcopy and Cervical Pathology, Frederick, MD. Updated consensus guidelines for managing abnormal cervical cancer screening tests and cancer precursors, april 2013. At: www.asccp.org/Portals/9/Algorithms%207.30.13.pdf. Accessed 20 Jan 2014.

  94. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Georgios Deftereos and Nancy B. Kiviat declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA, 15212, USA

    Georgios Deftereos

  2. Department of Pathology, Harborview Medical Center, University of Washington, 325 9th Ave, Ninth & Jefferson Bldg, Rm 2NJ-244, Seattle, WA, 98104, USA

    Nancy B. Kiviat

Authors
  1. Georgios Deftereos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy B. Kiviat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios Deftereos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deftereos, G., Kiviat, N.B. Detection and Clinical Management of Cervical Pathology in the Era of HPV. Curr Obstet Gynecol Rep 3, 107–115 (2014). https://doi.org/10.1007/s13669-014-0081-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13669-014-0081-z

Keywords

Search

Navigation